The [[Chinese Glioma Genome Atlas]] (CGGA) and The [[Cancer Genome Atlas]] (TCGA) [[database]]s with [[RNA sequencing]] and corresponding clinical data were dichotomized into training group and testing group. The immune-related differentially expressed genes (DEGs) associated with [[1p/19q codeletion]] were screened using Cox proportional hazards regression analyses. A prognostic [[gene signature]] was established using [[dataset]] from CGGA and tested in TCGA database. Subsequently, Xu et al. explored the correlation between the prognostic [[gene signature]] and [[immune response]]. Thirteen immune genes associated with 1p/19q codeletion were used to construct a prognostic signature. The 1-, 3-, 5-year survival rates of the low-risk group were approximately 97%, 89%, and 79%, while those of the high-risk group were 81%, 50% and 34%, respectively, in the training group. The nomogram which comprised age, WHO grade, primary or recurrent types, 1p/19q codeletion status and risk score provided accurate prediction for the survival rate of glioma. DEGs that were highly expressed in the high-risk group clustered with many immune-related pathways. [[Immune checkpoint]]s including TIM3, PD1, PDL1, CTLA4, TIGIT, MIR155HG, and CD48 were correlated with the risk score. VAV3 and TNFRFSF11B were found to be candidate immune checkpoints associated with prognosis. The 1p/19q codeletion-associated immune signature provides accurate prediction of OS. [[VAV3]] and [[TNFRFSF11B]] are novel immune checkpoints
((Xu J, Liu F, Li Y, Shen L. A 1p/19q Codeletion-Associated Immune Signature for Predicting Lower Grade Glioma Prognosis [published online ahead of print, 2020 Sep 7]. Cell Mol Neurobiol. 2020;10.1007/s10571-020-00959-3. doi:10.1007/s10571-020-00959-3)).